VIDEO: Tools to assess treatment benefits in patients with dry AMD ‘inadequate’

Disclosures:
Csaky reports consulting for AbbVie, Annexon Biosciences, Astellas, Boehringer Ingelheim Pharmaceuticals, Cognition Therapeutics, EyeBio, F. Hoffmann-La Roche AG, Genentech, Johnson & Johnson Health Care Systems, Merck, NGM Biopharmaceuticals, Novartis and Regeneron Pharmaceuticals and serving in a data and safety monitoring role for Adverum Biotechnologies.

This post was originally published on this site